Pumitamig + Nab-paclitaxel + Gemcitabine + mFOLFIRINOX

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pancreatic Ductal Adenocarcinoma (PDAC)

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Trial Timeline

Dec 4, 2025 → Aug 1, 2028

NCT ID

NCT07255404

About Pumitamig + Nab-paclitaxel + Gemcitabine + mFOLFIRINOX

Pumitamig + Nab-paclitaxel + Gemcitabine + mFOLFIRINOX is a phase 2 stage product being developed by Bristol Myers Squibb for Pancreatic Ductal Adenocarcinoma (PDAC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07255404. Target conditions include Pancreatic Ductal Adenocarcinoma (PDAC).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07255404	Phase 2	Recruiting	Dec 4, 2025	Aug 1, 2028	Pancreatic Ductal Adenocarcinoma (PDAC)

Competing Products

20 competing products in Pancreatic Ductal Adenocarcinoma (PDAC)

See all competitors

Product	Company	Stage	Hype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + Bendamustine	Lonza	Phase 1	30
pemetrexed	Eli Lilly	Phase 2	52
mFOLFIRINOX + Ramucirumab	Eli Lilly	Phase 2	52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359	Perspective Therapeutics	Phase 1/2	33
Zentalis + Gemzar	Zentalis Pharmaceuticals	Phase 2	44
enzastaurin + gemcitabine	Eli Lilly	Phase 2	52
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4	Eli Lilly	Phase 1	33
Ramucirumab	Eli Lilly	Phase 1/2	41
GEMZAR + ALIMTA	Eli Lilly	Phase 3	77
CS-1008 (humanized anti-DR5 antibody) + gemcitabine	Daiichi Sankyo	Phase 2	52
exatecan mesylate	Daiichi Sankyo	Phase 2	52
exatecan mesylate + gemcitabine hydrochloride	Daiichi Sankyo	Phase 3	77
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	52
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	52
AGS-1C4D4 + gemcitabine	Astellas Pharma	Phase 2	52
erlotinib + gemcitabine + nab-paclitaxel	Astellas Pharma	Phase 1	33
erlotinib hydrochloride + gemcitabine hydrochloride	Astellas Pharma	Phase 1	33
AGS-1C4D4 + Gemcitabine	Astellas Pharma	Phase 2	52
Tarceva (erlotinib HCl, OSI-774)	Astellas Pharma	Phase 3	77
Enzalutamide + Gemcitabine + Nab-paclitaxel	Astellas Pharma	Phase 1	33

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved